Oncotelic Therapeutics' Deciparticle Platform Demonstrates Versatility in Drug Delivery for Cancer and Immunology

Oncotelic Therapeutics Inc. is advancing next-generation drug delivery with its scalable nanotechnology platform that could reshape immunology and oncology treatments. The company's Deciparticle platform, leveraging clinical-stage nanomedicine Sapu Nano, demonstrated new capabilities at the 2025 San Antonio Breast Cancer Symposium. According to data presented, the platform can package even the most challenging water-resistant drugs into smaller, uniform nanoparticles suitable for safe intravenous administration.

The platform's compatibility across therapeutic categories represents a significant advancement. All five main macrolide mTOR inhibitors, including temsirolimus, sirolimus, ridaforolimus, Everolimus (Afinitor), and umirolimus, formed stable, monodisperse particles. Tacrolimus, a crucial immunosuppressant drug, also formed stable nanoparticles with diameters under 20 nanometers, highlighting the platform's ability to handle diverse drug structures. Complex peptides such as exenatide and cyclosporine A were successfully packaged, demonstrating the innovation works with both linear and cyclic peptides.

This technological breakthrough matters because traditional drug delivery methods often struggle with water-resistant compounds and complex peptides, limiting their therapeutic potential. The ability to create uniform nanoparticles under 20 nanometers enables more effective intravenous delivery, potentially improving drug bioavailability and reducing side effects. For oncology treatments, this could mean more precise targeting of cancer cells while minimizing damage to healthy tissues. In immunology, it could enhance the delivery of immunosuppressants and other therapeutic agents.

The implications extend beyond individual drug delivery to potentially transform treatment paradigms across multiple therapeutic areas. By overcoming formulation challenges that have historically limited certain drug classes, the Deciparticle platform could unlock new treatment options for patients with difficult-to-treat conditions. The platform's scalability suggests potential for broad application across the pharmaceutical industry, where drug formulation remains a significant bottleneck in development pipelines.

For investors and industry observers, the latest developments are available through the company's newsroom at https://ibn.fm/OTLC. The successful packaging of multiple drug classes indicates the platform's versatility and potential for licensing opportunities. As a clinical-stage biopharmaceutical company, Oncotelic's progress with this platform could accelerate development timelines for various therapeutic candidates, particularly in high-unmet-need cancers and rare pediatric indications where innovative delivery systems are urgently needed.